Life Sciences and Healthcare

Cystic fibrosis: Market shake-up to come?

This article, a Cortellis Market Insight report, is adapted from the author’s comprehensive Cystic Fibrosis Disease Report. Publication of the report coincides with Cystic Fibrosis Awareness Month in May in the U.S. and Canada, which aims to raise awareness and improve understanding of the disease. Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies have transformed […]

3 ways epic users tackle denials

Earlier this year, HBI hosted a roundtable discussion on analyzing and managing denials. This topic is of constant interest in HBI’s membership community, but best practices often vary by organization. For example, geography and size can shape payer and patient mix, staffing structures, and available technology—ultimately steering how revenue cycle leaders choose to handle denials. […]

In China 4+7 equals quality generic medicines at affordable costs

China is overhauling its healthcare system to align with the changing economic and demographic situation China’s healthcare system is undergoing a series of major reforms to the regulatory and reimbursement policies. These reforms are aimed at closing the demand gap for novel and cost-effective therapies, particularly those generally developed and available in the western countries […]

Oncology landscape stays hot for dealmakers

Intense competition for dealmaking in oncology “shows no sign of abating.” That’s the key takeaway from recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article, “Oncology dealmaking trends,” was featured in the Biopharma Dealmakers supplement to Nature Biotechnology and Nature Reviews: Drug Discovery. Munro, global practice leader, portfolio and licensing, […]

Immuno-oncology spotlight on diverse therapeutic classes

Immune checkpoint inhibitors, such as the multi-billion-dollar drugs Keytruda and Opdivo, have dominated the immuno-oncology landscape in recent years (see Figure 1), but are not the only classes on the market or in development. T-cell engager therapeutics, oncolytic virus therapy and adoptive T-cell therapies were among the promising technologies covered at the fourth annual Immuno-Oncology […]

How can I advance our value analysis committee?

Many hospitals and health systems have had long-standing value analysis committees in place for several years now. Traditionally, these committees often approved the purchase of new items based on price neutrality or savings. However, many value analysis committees are evolving past this model, finding it restrictive to introducing new technologies and ostracizing to clinicians. As […]

Drug development challenge: Managing CMC submissions

In the era of Breakthrough Therapy and Fast Track drug designations, chemistry, manufacturing and controls (CMC) submissions can cause delays to bring a drug to market, said Drew Barlow, vice president, regulatory affairs at Syner-G Pharma Consulting.  Companies need to provide enough information to satisfy the regulatory requirements while recognizing that providing too much information early will […]

Evolus Set to Enter the Aesthetic Botulinum Toxin Market – How will Competitors React?

Competition in the US aesthetic botulinum toxin market is set to increase with the launch of Evolus’ Jeuveau—the first new botulinum toxin approved by the FDA since Merz Pharma’s XEOMIN in 2010—this spring. In a market dominated by Allergan’s BOTOX, several investors and industry members have questioned how Evolus will enter this already competitive space […]

Virginia and West Virginia Ban Copay Accumulators. What’s Next?

In March 2019, Virginia and West Virginia became the first states in the nation to ban copay accumulators—an increasingly common benefit adjustment that prevents manufacturer drug coupons from paying-down patient deductibles and out-of-pocket maximums. Many employers and managed care organizations adopted these programs for the 2019 benefit year, and more are expected to follow in […]

Setting expectations for courier services providers

Recent mergers and acquisitions have resulted in a complex process of integrating individual care sites into an organization’s central network system. With an emphasis to reduce overhead and operating costs, hospitals should focus on centralizing their freight spend to generate cost savings. Organizations are generally aware of inbound and outbound shipment costs related to courier […]